Leukemia Research
Volume 29, Issue 2 , Pages 131-134 , February 2005

Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case

  • Joseph H. Butterfield

      Affiliations

    • Division of Allergic Diseases and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Ayalew Tefferi

      Affiliations

    • Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    • ,
  • Gerald F. Kozuh

      Affiliations

    • Oncology Joint Practice, Wheaton, IL, USA

Received 12 May 2004 ,Accepted 20 May 2004.

References 

  1. Valent P. Biology, classification and treatment of human mastocytosis. Wien. Klin. Wochenschr. 1996;108:385–397
  2. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 2001;25:603–625
  3. Keyzer JJ, de Monchy JG, van Doormaal JJ, van Voorst Vader PC. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N. Engl. J. Med. 1983;309:1603–1605
  4. Roberts LJ, Sweetman BJ, Lewis RA, Austen KF, Oates JA. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N. Engl. J. Med. 1980;303:1400–1404
  5. Wodnar-Filipowicz A, Heusser CH, Moroni C. Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature. 1989;339:150–152
  6. Moller A, Lippert U, Lessmann D, Kolde G, Hamann K, Welker P, et al.  Human mast cells produce IL-8. J. Immunol. 1993;151:3261–3266
  7. Grabbe J, Welker P, Moller A, Dippel E, Ashman LK, Czarnetzki BM. Comparative cytokine release from human monocytes, monocyte-derived immature mast cells, and a human mast cell line (HMC-1). J. Invest. Dermatol. 1994;103:504–508
  8. Tunon de Lara JM, Okayama Y, McEuen AR, Heusser CH, Church MK, Walls AF. Release and inactivation of interleukin-4 by mast cells. Ann. N.Y. Acad. Sci. 1994;725:50–58
  9. Bradding P, Holgate ST. The mast cell as a source of cytokines in asthma. Ann. N.Y. Acad. Sci. 1996;796:272–281
  10. Toru H, Pawankar R, Ra C, Yata J, Nakahata T. Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. J. Allergy Clin. Immunol. 1998;102:491–502
  11. Hirschowitz BI, Groarke JF. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Ann. Intern. Med. 1979;90:769–771
  12. Soter NA, Austen KF, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N. Engl. J. Med. 1979;301:465–469
  13. Lewis RA. Mastocytosis. J. Allergy Clin. Immunol. 1984;74:755–765
  14. Butterfield JH, Kao PC, Klee GC, Yocum MW. Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin. Proc. 1995;70:481–487
  15. Granerus G, Lonnqvist B, Roupe G. Histamine metabolism in mastocytosis patients treated with interferon α-2b. Inflamm. Res. 1996;45(Suppl. 1):S41–S43
  16. Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk. Lymphoma. 1996;22:501–508
  17. Casassus P, Caillat-Vigneron N, Martin A, Simon J, Gallais V, Beaudry P, et al.  Treatment of adult systemic mastocytosis with inferon-α: results of a multicentre phase II trial on 20 patients. Br. J. Haematol. 2002;119:1090–1097
  18. Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, et al.  Response to inferferon alfa-2b in a patient with systemic mastocytosis. N. Engl. J. Med. 1992;326:619–623
  19. Harrison BD, Ashford RA, Hatton CS. Systemic mastocytosis—a case treated with interferon α and radiotherapy. Clin. Lab. Haematol. 1994;16:291–294
  20. Petit A, Pulik M, Gaulier A, Lionnet F, Mahe A, Sigal M. Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon alfa therapy. J. Am. Acad. Dermatol. 1995;32:850–853
  21. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br. J. Dermatol. 1998;138:489–495
  22. Pulik M, Lionnet F, Petit A, Genet P, Gaulier A. Long-term response to interferon-α in a patient with systemic mastocytosis and chronic myelomonocytic leukemia (letter to the editor). Am. J. Hematol. 1994;47:66
  23. Kolde G, Sunderkotter C, Luger TA. Treatment of urticaria pigmentosa using interferon alpha. Br. J. Dermatol. 1995;133:91–94
  24. Delaporte E, Piérard E, Wolthers BG, Desreumaux P, Janin A, Cortot A, et al.  Interferon-α in combination with corticosteroids improves systemic mast cell disease. Br. J. Dermatol. 1995;132:479–482
  25. Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pflüger K-H. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann. Hematol. 1996;72:41–43
  26. Czarnetzki BM, Algermissen B, Jeep S, Haas N, Nurnberg W, Muller K, et al.  Interferon treatment of patients with chronic urticaria and mastocytosis. J. Am. Acad. Dermatol. 1994;30:500–501
  27. Pardini S, Bosincu L, Bonfigli S, Dore F, Longinotti M. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon. Acta Haematol. 1991;85:220
  28. Irani AA, Nilsson G, Ashman LK, Schwartz LB. Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor. Immunology. 1995;84:72–78
  29. Finotto S, Mekori YA, Metcalfe DD. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J. Clin. Invest. 1997;99:1721–1728

PII: S0145-2126(04)00217-6

doi: 10.1016/j.leukres.2004.05.003

Leukemia Research
Volume 29, Issue 2 , Pages 131-134 , February 2005

Article Tools

* Image Usage & Resolution